The stock of Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has increased by 2.14 when compared to last closing price of 17.75. Despite this, the company has experienced a 0.55% gain in its stock price over the last five trading sessions. zacks.com reported 2024-07-16 that Acadia Pharmaceuticals ACAD is a commercial-stage company focused on developing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders and rare diseases. ACAD’s commercial portfolio comprises two marketed drugs — Nuplazid (pimavanserin) and Daybue (trofinetide).
Is It Worth Investing in Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Right Now?
The stock has a 36-month beta value of 0.38. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ACAD is 164.01M, and at present, short sellers hold a 7.27% of that float. On July 23, 2024, the average trading volume of ACAD was 1.72M shares.
ACAD’s Market Performance
The stock of Acadia Pharmaceuticals Inc (ACAD) has seen a 0.55% increase in the past week, with a 22.92% rise in the past month, and a 7.79% gain in the past quarter. The volatility ratio for the week is 3.39%, and the volatility levels for the past 30 days are at 3.73% for ACAD. The simple moving average for the last 20 days is 8.16% for ACAD stock, with a simple moving average of -14.71% for the last 200 days.
Analysts’ Opinion of ACAD
Many brokerage firms have already submitted their reports for ACAD stocks, with BMO Capital Markets repeating the rating for ACAD by listing it as a “Outperform.” The predicted price for ACAD in the upcoming period, according to BMO Capital Markets is $31 based on the research report published on June 27, 2024 of the current year 2024.
Needham, on the other hand, stated in their research note that they expect to see ACAD reach a price target of $32, previously predicting the price at $36. The rating they have provided for ACAD stocks is “Buy” according to the report published on March 12th, 2024.
Mizuho gave a rating of “Neutral” to ACAD, setting the target price at $25 in the report published on March 12th of the current year.
ACAD Trading at 14.70% from the 50-Day Moving Average
After a stumble in the market that brought ACAD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.37% of loss for the given period.
Volatility was left at 3.73%, however, over the last 30 days, the volatility rate increased by 3.39%, as shares surge +18.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.84% upper at present.
During the last 5 trading sessions, ACAD rose by +0.55%, which changed the moving average for the period of 200-days by -12.75% in comparison to the 20-day moving average, which settled at $16.90. In addition, Acadia Pharmaceuticals Inc saw -42.10% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACAD starting from Schneyer Mark C., who sale 975 shares at the price of $14.79 back on Jun 10 ’24. After this action, Schneyer Mark C. now owns 34,564 shares of Acadia Pharmaceuticals Inc, valued at $14,420 using the latest closing price.
DAVIS STEPHEN, the CEO of Acadia Pharmaceuticals Inc, sale 11,427 shares at $16.94 during a trade that took place back on May 02 ’24, which means that DAVIS STEPHEN is holding 155,231 shares at $193,573 based on the most recent closing price.
Stock Fundamentals for ACAD
Current profitability levels for the company are sitting at:
- -0.01 for the present operating margin
- 0.92 for the gross margin
The net margin for Acadia Pharmaceuticals Inc stands at -0.0. The total capital return value is set at -0.01. Equity return is now at value -0.41, with -0.23 for asset returns.
Based on Acadia Pharmaceuticals Inc (ACAD), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at 1.07.
Currently, EBITDA for the company is -67.83 million with net debt to EBITDA at -56.24. When we switch over and look at the enterprise to sales, we see a ratio of 3.5. The receivables turnover for the company is 8.13for trailing twelve months and the total asset turnover is 0.95. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.04.
Conclusion
To sum up, Acadia Pharmaceuticals Inc (ACAD) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
